NovaBridge Biosciences (NBP) Interest Coverage Ratio (2019)
NovaBridge Biosciences (NBP) posted quarterly Interest Coverage Ratio of 288.14 for Q4 2025, down 408.58% year-over-year from 93.38 in Q4 2024, and down 60721.14% quarter-over-quarter from 0.47 in Q3 2025.
Analysis
NovaBridge Biosciences (NBP) Interest Coverage Ratio (2019) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Interest Coverage Ratio for 5 consecutive years, with 288.14 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Coverage Ratio fell 408.58% year-over-year to 288.14; the TTM figure through Dec 2025 stood at 131.11 (down 18.81% YoY), while the FY2025 annual figure was 1.23, down 34.47% from the prior year.
- Interest Coverage Ratio declined to 288.14 in Q4 2025 per NBP's latest filing, from 0.47 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.47 in Q3 2025 and bottomed at 288.14 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 67.74 across 3 years, with a median of 29.82 in 2024.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio plunged 897.06% — and 2025, when it soared 99.12%.
- NovaBridge Biosciences' Interest Coverage Ratio stood at 5.68 in 2023, then slumped by 897.06% to 56.66 in 2024, then tumbled by 408.58% to 288.14 in 2025.
- Business Quant data shows NBP's Interest Coverage Ratio at 288.14 in Q4 2025, 0.47 in Q3 2025, and 1.54 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |